TAPUR
Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)
What's the purpose of the trial?
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.
Accepting patients
![](https://maps.googleapis.com/maps/api/staticmap?key=AIzaSyDXH19UJTDtS-I9fdYHjFXupEiuQkBgRPk&size=520x280&scale=1&maptype=raodmap&markers=icon%3Ahttps%3A%2F%2Fassets.sparkcures.com%2Fimg%2Fmaps%2Fhospital-default.png%7C42.282101%2C-83.727303%7C35.2062%2C-80.838203%7C44.760898%2C-85.642524%7C41.255507%2C-95.979724%7C33.453974%2C-112.364512%7C33.3848%2C-84.757698%7C42.448799%2C-87.827698%7C46.884899%2C-96.786003%7C46.807999%2C-100.781998%7C45.527%2C-122.613998%7C43.537701%2C-96.743896%7C47.607114%2C-122.309471%7C29.707199%2C-95.396698%7C38.859901%2C-77.226196%7C40.071602%2C-75.089996%7C33.792801%2C-84.319504%7C25.7887%2C-80.2146%7C33.506452%2C-86.802573%7C21.30847%2C-157.853858%7C39.899766%2C-86.044117%7C40.566494%2C-75.523828%7C38.944682%2C-121.09885%7C38.571217%2C-121.470032%7C37.439638%2C-122.162051%7C26.186668%2C-80.119653%7C44.363485%2C-69.784993%7C44.770446%2C-68.728455%7C44.144106%2C-69.084227%7C43.196631%2C-71.561824%7C37.791239%2C-122.432281%7C39.696066%2C-84.190037%7C32.028228%2C-81.101957%7C35.094183%2C-106.553714%7C35.095872%2C-106.627734%7C40.839802%2C-73.939301%7C41.754562%2C-72.679234%7C41.675107%2C-72.822565%7C41.827709%2C-73.104325%7C39.136822%2C-84.503548%7C35.903011%2C-79.053528%7C42.66562%2C-88.309638%7C43.218997%2C-88.131616%7C43.32361%2C-87.928354%7C44.474964%2C-87.942288%7C42.573486%2C-87.948165%7C45.070883%2C-87.648009%7C42.990923%2C-87.950322%7C43.042609%2C-87.928195%7C43.001367%2C-88.023419%7C44.027528%2C-88.595628%7C42.720395%2C-87.890195%7C43.758284%2C-87.737499%7C43.0438%2C-88.047997%7C37.825571%2C-122.258388%7C38.746619%2C-121.250764%7C38.58247%2C-121.499197%7C37.658482%2C-122.438319%7C37.783512%2C-122.440678%7C37.239511%2C-121.802145%7C37.706487%2C-122.164705%7C37.335942%2C-121.99708%7C38.127547%2C-122.248461%7C37.891507%2C-122.058014%7C40.756828%2C-73.70179%7C36.153613%2C-86.81075%7C42.265496%2C-85.650036%7C42.266079%2C-83.655507%7C42.558309%2C-83.793897%7C42.294315%2C-83.488056%7C42.507508%2C-83.004115%7C42.495783%2C-82.986363%7C43.023981%2C-83.667416%7C43.426033%2C-83.941713%7C44.263839%2C-84.246145%7C42.394555%2C-83.404364%7C42.612895%2C-83.275854%7C42.50598%2C-83.004712%7C40.949234%2C-75.963787%7C42.047596%2C-86.45893%7C43.205564%2C-86.208822%7C42.969485%2C-85.665%7C42.283662%2C-85.580836%7C35.303147%2C-81.531427%7C35.21955%2C-80.853131%7C35.147152%2C-80.82455%7C35.091849%2C-80.871391%7C34.974866%2C-80.521358%7C35.305139%2C-80.746645%7C35.057217%2C-80.854663%7C34.980078%2C-80.989266%7C35.364263%2C-80.193173%7C35.34297%2C-80.762707%7C35.49024%2C-81.202565%7C34.337579%2C-78.694559%7C35.725654%2C-81.654612%7C35.747621%2C-81.522356%7C35.340712%2C-81.900998%7C35.269274%2C-81.132406%7C35.094498%2C-80.676222%7C37.096802%2C-113.553971%7C37.701104%2C-113.063939%7C40.757409%2C-111.880166%7C41.137248%2C-95.948%7C47.6092%2C-122.324109%7C47.608464%2C-122.32148%7C47.669998%2C-122.370003%7C47.802015%2C-122.331369%7C45.510153%2C-122.771881%7C45.307787%2C-122.935818%7C45.429562%2C-122.569253%7C38.862856%2C-77.223717%7C38.884122%2C-77.380061%7C38.854053%2C-77.22354%7C37.790622%2C-122.43217%7C38.765232%2C-121.248419%7C37.369797%2C-122.082375%7C37.368344%2C-122.029722%7C36.988051%2C-121.982235%7C37.786111%2C-122.457591%7C37.548408%2C-121.974446%7C38.131468%2C-122.240506%7C38.236797%2C-122.086046%7C37.653142%2C-120.97383%7C37.591808%2C-122.383739%7C37.521295%2C-122.33657%7C37.85829%2C-122.259622%7C37.864072%2C-122.268712%7C38.48325%2C-122.739682%7C34.066644%2C-118.389389%7C33.853199%2C-118.378998%7C29.775281%2C-95.715784%7C29.550928%2C-95.086306%7C29.604876%2C-95.620004%7C30.202713%2C-95.458861%7C39.7868%2C-86.075112%7C39.639687%2C-86.134554%7C40.446841%2C-86.126157%7C25.686531%2C-80.350846%7C25.972869%2C-80.14645%7C33.908771%2C-84.349029%7C33.768566%2C-84.386118%7C34.06623%2C-84.176209%7C43.638946%2C-70.323832%7C43.894808%2C-69.967964%7C43.600384%2C-70.317696%7C44.209555%2C-70.532436%7C44.412558%2C-68.994038%7C43.600384%2C-70.317696%7C43.403636%2C-70.703043%7C43.478281%2C-70.487916%7C43.406484%2C-70.564817%7C43.93585%2C-69.984356%7C43.062327%2C-70.794064%7C44.8074%2C-68.752602%7C44.770446%2C-68.728455%7C42.983409%2C-71.437995%7C43.09634%2C-70.750681%7C43.322168%2C-70.587776%7C43.147823%2C-70.641802%7C32.027829%2C-81.100126%7C32.272268%2C-80.916803%7C32.223794%2C-80.712142%7C39.771059%2C-84.062827%7C40.042922%2C-84.209585%7C39.41588%2C-84.572824%7C41.542541%2C-72.088877%7C41.549306%2C-72.801145%7C41.201351%2C-73.201254%7C41.717343%2C-72.225933%7C32.290305%2C-106.736473%7C35.218898%2C-106.696234%7C43.159499%2C-88.508281%7C44.125149%2C-87.61966%7C43.14755%2C-87.948765%7C40.764166%2C-73.963543%7C40.753428%2C-73.708202%7C41.108607%2C-73.864302%7C36.325396%2C-86.622424%7C36.176726%2C-86.607715%7C35.860716%2C-86.426481%7C35.91741%2C-86.814934%7C36.357253%2C-86.537011%7C36.010004%2C-87.329035%7C36.179685%2C-86.326796%7C35.566523%2C-86.451745%7C35.974275%2C-86.566098%7C36.244852%2C-86.749707%7C36.152048%2C-86.801153%7C36.076219%2C-86.723328%7C28.205427%2C-82.661676%7C26.151704%2C-81.799427%7C29.6388%2C-82.3424%7C35.749968%2C-81.525476%7C35.436427%2C-80.603133%7C42.310029%2C-84.016908%7C42.419596%2C-82.911243%7C42.787216%2C-82.479887%7C42.670322%2C-82.944666%7C42.50598%2C-83.003959%7C43.023981%2C-83.667416%7C42.733547%2C-84.53518%7C43.478626%2C-83.996584%7C44.275185%2C-83.509853%7C40.645465%2C-75.405837%7C40.992205%2C-75.1723%7C42.330333%2C-85.180396%7C42.958132%2C-85.662315%7C43.878678%2C-85.521583%7C42.292908%2C-85.586373%7C42.857532%2C-85.718772%7C41.257797%2C-96.188867%7C47.535856%2C-122.021493%7C34.047307%2C-118.462978%7C25.71344%2C-80.280069%7C26.108357%2C-80.255742%7C26.300676%2C-80.12258%7C43.600384%2C-70.317696%7C35.086147%2C-106.639953%7C36.115986%2C-86.848007%7C25.788279%2C-80.213952%7C37.790622%2C-122.43217%7C43.024061%2C-83.66759%7C32.272268%2C-80.916803%7C32.272268%2C-80.916803%7C47.535856%2C-122.021493%7C43.142504%2C-70.652065%7C32.030447%2C-81.094134%7C34.075199%2C-118.379997%7C42.419596%2C-82.911243%7C39.357565%2C-84.368041%7C38.48325%2C-122.739682%7C32.028228%2C-81.101957%7C40.599998%2C-74.07)
Participating Centers
There are 233 centers participating in this trial. Enter a location below to find the closest center.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- Larotrectinib is a first generation tropomyosin kinase (TRK) inhibitor used in the treatment of cancers that have TRK fusions.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.